Theravance Biopharma (TBPH) investor relations material

Financial position and business outlook

• Over $300 million in cash, no debt, and $175 million in high-probability milestones expected.

• YUPELRI generates $45 million in annual positive cash flow, with revenue growth projected for several years and exclusivity likely until 2039.

• Company is essentially cash flow break even, with rare disease launches expected to require focused, measured capital investment.

• Monetization of Trilogy royalties recently completed.

Ampreloxetine development and market opportunity

• Phase 3 CYPRESS study for ampreloxetine in multiple system atrophy (MSA) with neurogenic orthostatic hypotension (NOH) completed enrollment; data expected in Q1 next year.

• Ampreloxetine aims to address core symptoms of autonomic failure, improving patient mobility and quality of life.

• Market analysis estimates 40,000–50,000 MSA patients in the U.S., with 80% suffering from NOH.

• Competitive therapies have limited durability and safety concerns; ampreloxetine offers once-daily dosing and no black box for supine hypertension.

• Pre-launch activities include direct relationship-building with treating physicians and tailored rare disease launch planning.

Commercial strategy and product execution

• Commercial organization build-out will be deliberate and resource-efficient, with hiring contingent on positive Phase 3 data.

• Rare disease launch will leverage claims analysis to efficiently target patient populations and allocate resources.

• YUPELRI commercial focus is on maximizing patient persistence post-hospital discharge and expanding community impact.

• Partnership with Viatris is key to YUPELRI’s hospital and community strategy, with both companies working to improve patient persistence.

• YUPELRI recently approved in China; launch expected next year, with company holding a passive royalty interest.